Values as of: 2025-05-19
COMMON STOCK | Biotechnology |
Last Closing
USD 8.71Change
+0.15 (+1.75)%Market Cap
USD 0.91BVolume
1.23MAnalyst Target
USD 38.67Verdict
Verdict
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Company Website : https://www.arcusbio.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| TECH | Bio-Techne Corp |
+0.13 (+0.26%) |
USD 8.03B |
| BHVN | Biohaven Pharmaceutical Holdin.. |
-0.27 (-1.69%) |
USD 1.64B |
| NUVB | Nuvation Bio Inc |
+0.04 (+1.77%) |
USD 0.77B |
| DNA | Ginkgo Bioworks Holdings |
+0.16 (+2.02%) |
USD 0.46B |
| CYBN | Cybin Inc |
+0.78 (+11.61%) |
USD 0.15B |
| ADCT | ADC Therapeutics SA |
+0.45 (+23.81%) |
USD 0.14B |
| PLX | Protalix Biotherapeutics Inc |
+0.01 (+0.60%) |
USD 0.13B |
| OSTX | OS Therapies Incorporated |
-0.05 (-3.05%) |
USD 0.07B |
| ANRO | Alto Neuroscience, Inc. |
+0.01 (+0.40%) |
USD 0.07B |
| ATNM | Actinium Pharmaceuticals Inc |
+0.12 (+7.19%) |
USD 0.05B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -41.50% | 34% | F | 3% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -41.50% | 34% | F | 3% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -48.09% | 54% | F | 5% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -48.09% | 54% | F | 4% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -76.18% | 43% | F | 4% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -76.18% | 43% | F | 3% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -11.28% | 32% | F | 6% | D- | ||
| Dividend Return | -11.28% | 32% | F | 5% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 31.20% | 84% | B | 29% | F | ||
| Risk Adjusted Return | -36.16% | 24% | F | 8% | B- | ||
| Market Capitalization | 0.91B | 93% | A | 56% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
